Psilocybin-assisted therapy is a structured treatment that combines a psychoactive compound found in certain mushrooms with professional psychological support to treat depression, anxiety, addiction, and other mental health conditions. Unlike daily antidepressants, it typically involves just one or two dosing sessions, with preparation beforehand and integration afterward. The approach has shown striking results in clinical trials, and the FDA granted it “Breakthrough Therapy” status in 2019 for treatment-resistant depression.
How It Works in the Brain
Psilocybin acts on serotonin receptors in the brain, triggering a cascade of changes in how brain regions communicate with each other. Its most significant effect is on the default mode network, a group of brain areas responsible for your sense of self, rumination, and the mental chatter that dominates everyday thinking. During a psilocybin session, activity in this network decreases sharply, which is thought to loosen rigid patterns of thought, especially the kind of repetitive negative thinking characteristic of depression.
At the same time, psilocybin increases what researchers call brain entropy: the variety of neural states your brain can access. Regions that don’t normally talk to each other form new temporary connections, creating a window of heightened flexibility in cognition and emotion. This temporary reorganization is believed to be what allows emotional breakthroughs during sessions. One prominent theory, known as the “relaxed beliefs” model, proposes that psychedelics reduce the grip of prior beliefs and expectations on perception, letting new perspectives emerge from the bottom up rather than being filtered through old assumptions. In practical terms, many patients describe feeling “unstuck” for the first time in years.
What a Treatment Protocol Looks Like
Psilocybin-assisted therapy is not simply taking a pill. It follows a three-phase structure: preparation, dosing, and integration.
In preparation sessions, a therapist or pair of facilitators meets with you to build trust, discuss your mental health history, set intentions for the experience, and explain what to expect. This phase typically spans one to three sessions over several days or weeks before dosing day.
The dosing session itself lasts roughly six to eight hours. In clinical trials, participants receive a single oral dose, usually 25 mg of synthetic psilocybin for a full therapeutic effect. A 10 mg dose has been tested but did not show significant benefit over a control dose in one major trial. During the session, you lie down in a comfortable room, often with eye shades and a curated music playlist, while one or two trained facilitators remain present. They don’t lead a traditional therapy conversation. Instead, they provide reassurance and gentle guidance, encouraging you to turn inward and stay with whatever emotions, imagery, or memories arise.
Integration sessions follow in the days and weeks after dosing. These are where you process the experience with your therapist, making sense of insights and connecting them to your everyday life. Many researchers believe this phase is essential to translating an acute psychedelic experience into lasting psychological change.
Clinical Results for Depression
The numbers from clinical trials have been unusually strong for a psychiatric treatment. In a trial of cancer patients with depression and anxiety, 92% of those receiving a high dose showed a clinically significant response at five weeks, compared to 32% in a low-dose control group. Remission rates were 60% versus 16%. At a six-month follow-up, roughly 80% of participants across both groups (after crossover) maintained clinically significant decreases in depressed mood and anxiety.
For major depressive disorder specifically, a phase 2 trial published in the New England Journal of Medicine compared psilocybin to escitalopram, a widely prescribed SSRI. After six weeks, 57% of the psilocybin group achieved remission compared to 28% in the escitalopram group. Another trial found that 14 out of 26 patients given psilocybin met remission criteria within two weeks, versus 3 out of 26 on placebo. In treatment-resistant depression, a single 25 mg dose reduced depression scores significantly more than a 1 mg control dose over three weeks in a phase 2 trial involving 233 participants.
One notable difference from conventional antidepressants: SSRIs typically take several weeks to begin working and require daily dosing. Psilocybin’s effects often appear within days of a single session.
How Long the Effects Last
One of the most important questions is whether the benefits hold up over time. An open-label study of patients with major depression found that 75% still met response criteria and 58% remained in remission at 12 months after treatment. A smaller pilot study in military veterans with severe treatment-resistant depression showed a more tempered picture: at six months, 80% met response criteria and 50% were in remission, but by 12 months those numbers had dropped to 40% and 30% respectively. Depression scores began to climb noticeably around the nine-month mark.
These findings suggest that for some people, a single dosing session may provide lasting relief for a year or longer, while others may need a “booster” session at some point. Researchers are still working out the optimal retreatment schedule, and the severity of someone’s depression before treatment appears to influence how long the effects persist.
Conditions Beyond Depression
Depression has been the primary focus, but psilocybin-assisted therapy is being studied across a range of conditions. Trials have investigated its use for tobacco addiction, alcohol use disorder, obsessive-compulsive disorder, and depression and anxiety in people facing life-threatening diagnoses such as terminal cancer. Early-stage research is also exploring its potential for PTSD. In most of these areas, the evidence is still limited to small trials, but the initial findings have been promising enough to attract significant research funding and pharmaceutical investment.
Side Effects and Risks
The acute experience can include nausea, headache, dizziness, increased blood pressure and heart rate, fatigue, and anxiety or paranoia. These effects are temporary and typically resolve within hours of the session. Some participants report poor sleep for a night or two afterward. In clinical trials, the rate of adverse events was similar between psilocybin and escitalopram groups, suggesting the side effect burden is comparable to standard antidepressants, though the nature of the effects is quite different.
The more serious concern is psychological. Psilocybin can trigger intense emotional states, including fear, confusion, and distressing hallucinations, sometimes called a “challenging experience” or colloquially a “bad trip.” In a supervised clinical setting with trained facilitators, these episodes can typically be managed safely and sometimes even become therapeutically productive. Outside that setting, the risks increase substantially.
Psilocybin is not safe for people with psychotic conditions such as schizophrenia or schizoaffective disorder, or severe forms of bipolar disorder and borderline personality disorder. These conditions are strict exclusion criteria in every clinical trial because psilocybin could trigger or worsen psychotic episodes.
Regulatory Status
Psilocybin remains a Schedule I controlled substance in the United States at the federal level, meaning it is classified as having no accepted medical use and a high potential for abuse. Despite this classification, the FDA granted Breakthrough Therapy designation to two psilocybin programs: one from COMPASS Pathways for treatment-resistant depression in October 2018, and another from the Usona Institute for major depressive disorder in November 2019. This designation does not mean approval. It creates a faster pathway for development and closer collaboration between drug sponsors and the FDA on trial design and safety.
Phase 3 trials, the final stage before potential FDA approval, are ongoing. A handful of U.S. states and cities have moved independently to decriminalize or create regulated access frameworks for psilocybin, with Oregon being the first state to establish a licensed psilocybin therapy program. In most of Europe, psilocybin similarly remains a controlled substance, though clinical trials are active across several countries.